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The activity, localization and fate of many cellular proteins are regulated through ubiquitination, a
process whereby one or more ubiquitin (Ub) monomers or chains are covalently attached to
target proteins. While Ub-conjugated and Ub-associated proteomes have been described, we lack a
high-resolution picture of the dynamics of ubiquitination in response to signaling. In this study,
we describe the epidermal growth factor (EGF)-regulated Ubiproteome, as obtained by two
complementary puriﬁcation strategies coupled to quantitative proteomics. Our results unveil the
complex impact of growth factor signaling on Ub-based intracellular networks to levels that extend
well beyond what might have been expected. In addition to endocytic proteins, the EGF-regulated
Ubiproteome includes a large number of signaling proteins, ubiquitinating and deubiquitinating
enzymes, transporters and proteins involved in translation and transcription. The Ub-based
signaling network appears to intersect both housekeeping and regulatory circuitries of cellular
physiology. Finally, as proof of principle of the biological relevance of the EGF-Ubiproteome, we
demonstrated that EphA2 is a novel, downstream ubiquitinated target of epidermal growth factor
receptor (EGFR), critically involved in EGFR biological responses.
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Introduction
Post-translational modiﬁcations (PTMs) control the function
of many proteins and are crucial to the regulation of many
cellular processes, as exempliﬁed by the role of phosphoryla-
tion in signaling. The reversible addition of a small phosphate
group to protein substrates allows the propagation
of information through multiple mechanisms, including
activation/deactivation of the enzymatic properties of phos-
phorylated substrates, regulation of their subcellular localiza-
tion, and their recognition by speciﬁc domains present in
partner proteins (Seet et al, 2006). In another instance of PTM,
a more complex molecule, ubiquitin (Ub), is appended by E3
ligases to a multitude of substrates, thereby modulating their
function, localization and protein/protein interaction abilities
(Mukhopadhyay and Riezman, 2007; Ravid and Hochstrasser,
2008). Deubiquitinating enzymes (DUBs) revert Ub conjuga-
tion, thus ensuring a dynamic equilibrium between pools of
ubiquitinated and deubiquitinated proteins (Amerik and
Hochstrasser, 2004). Particularly relevant to signaling is the
ability of the Ub modiﬁcation to induce de novo protein/pro-
tein interactions, similarly to phosphorylation, through the
recognition of ubiquitinated proteins by proteins harboring
Ub-binding domains (Hicke et al, 2005; Hurley et al, 2006).
This mechanism sits at the heart of several signaling cascades
(Mukhopadhyay and Riezman, 2007; Woelk et al, 2007; Chen
and Sun, 2009), and is tightly controlled within the cell by
endogenous and exogenous signals, such as DNA damage and
growth factor stimulation, respectively (Chen and Sun, 2009).
In this latter instance, one of the best-characterized model
systems is represented by the epidermal growth factor (EGF)-
induced pathway. Upon EGF stimulation, a variety of proteins
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(EGFR), which undergoes both multiple monoubiquitination
(Haglund et al, 2003) and K63-linked polyubiquitination
(Huang et al, 2006), as well as components of the downstream
endocytic machinery, which are modiﬁed by monoubiquitina-
tion (Polo et al, 2002; Mukhopadhyay and Riezman, 2007).
The impact of ubiquitination on receptor internalization,
intracellular sorting and ultimate metabolic fate has been
characterized in detail for various receptors, including the
EGFR (Acconcia et al, 2009).
Little is known, however, about the wider impact of EGF-
induced ubiquitination on cellular homeostasis and on the
pleiotropic biological functions of the EGFR. A decisive step
in this direction would be the acquisition of the repertoire of
proteins that are ubiquitinated upon EGF stimulation; i.e., the
EGF-Ubiproteome. This study was undertaken to address this
issue.Recentadvancesinquantitativemassspectrometryhave
allowed the study of PTMs on a global scale (Jensen, 2006;
Choudhary et al, 2009). In this study, we combined two
different puriﬁcation procedures with high resolution, high
accuracy MS, coupled to an efﬁcient quantitation strategy, to
obtain the ﬁrst view of the EGF-induced Ubiproteome.
Results
Puriﬁcation of Ub-conjugated proteins
Owing to the low abundance and labile nature of ubiquitinated
proteins, the most critical step in their identiﬁcation is the
enrichment and puriﬁcation procedure. This is particularly
relevant in our case, as we are interested in the EGF-induced
Ubiproteome. Under these conditions, ubiquitination is a rapid,
dynamic process, and ubiquitinatedsubstrates are presentin the
cell at low stoichiometries and in a time-limited manner. To
maximizetherecoveryofubiquitinatedsubstrates,therefore,we
used an integrated approach based on two different puriﬁcation
strategies and two cellular model systems (see schematic
representation in Supplementary Figure S1).
Intheﬁrstpuriﬁcationscheme,amousemonoclonalantibody
(FK2) that recognizes both mono- and polyubiquitinated
species, but not free Ub, was used to immunopurify ubiquiti-
nated proteins from HeLa cell lysates. This approach (hereafter,
the ‘endogenous’ approach) allows the puriﬁcation of proteins
modiﬁedbyendogenous Ub, in the absence of any manipulation
of the cellular system (see Supplementary information and
legend to Supplementary Figure S1 for details).
In an alternative strategy (hereafter, the tandem afﬁnity
puriﬁcation ‘TAP’ approach), we exploited TAP. We developed
a tandem afﬁnity tag, consisting of a hexahistidine and a FLAG
sequence fused to Ub (FLAG-His-Ub). This construct was
transfected into B82L-EGFR cells, a mouse ﬁbroblast cell line
expressing human EGFR that has been widely used to study
EGF-dependent signaling (Chen et al, 1989). The TAP method
should allow the isolation of highly puriﬁed ubiquitinated
proteins, as fully denaturing conditions (8M urea) are used,
which dissolve most weak protein/protein interactions.
To overcome possible non-physiological and/or toxic effects
oftheoverexpressionofUb(Tagwerkeretal,2006),wechosea
TET-on inducible system (see Supplementary information for
details). The level of expression of tagged Ub at different time
points was assessed by immunoﬂuorescence and immunoblot
analysis (Figure 1A and B). Detection of high-molecular-
weight Ub signals conﬁrmed that the tagged Ub is functional
and is conjugated to proteins (Figure 1B). Tagged Ub was
expressed at one-tenth of the level of endogenous Ub
(Figure 1C), sufﬁcient to maintain the inducibility of the
EGF-mediated process, as monitored by monoubiquitination
of Eps15 (Figure 1D and Supplementary information). Finally,
B82L-EGFR cells overexpressing FLAG-His-Ub displayed the
same growth rate as untransfected cells (data not shown),
indicating that the expression of the tagged Ub had no major
toxic effect. We note that the ‘endogenous’ approach and the
‘TAP’ approach are not directly comparable as they are
performed in different cellular systems. This was due to our
inability to select a stable HeLa cell line expressing this tagged
version of Ub. However, we reasoned that the use of a second
cellular system, which differs both in terms of species and
of tissue origin, might in some respects be advantageous, as it
could lead to the identiﬁcation of a common repertoire of
ubiquitinated substrates.
For both approaches, the puriﬁcation procedure was
carefully set up and the yield was calculated to be 8% for
the ‘endogenous’ approach and 20% for the ‘TAP’ approach
(see Supplementary information and legend to Supplementary
Figure S1 for details). Representative quality control experi-
ments are presented in Figure 1E–H.
Of note, we performed a mock puriﬁcation for the
‘endogenous’ approach by omitting the FK2 Ab in the
puriﬁcation scheme, and an I-DIRTexperiment in the case of
the‘TAP’approach(see‘controlendogenous’and‘I-DIRTTAP’
sheets in Supplementary Table S1 and Supplementary Figure
S2). These experiments were used to ﬁlter out proteins that
were non-speciﬁcally recovered during the puriﬁcation proce-
dures (see Supplementary information for details).
Identiﬁcation of steady-state Ubiproteomes
Our ultimate goal was the identiﬁcation of the EGF-induced
Ubiproteome. Thus, we employed high resolution, high
accuracy MS (Olsen et al, 2005) combined with stable isotope
labeling with amino acids in cell culture (SILAC) (Ong and
Mann, 2006) to distinguish the EGF-dependent ubiquitination
events from the high background of steady-state ubiquitinated
proteins. This strategyallowed the identiﬁcation and quantita-
tion of the steady-state HeLa and B82L-EGFR Ubiproteomes
and the speciﬁc EGF-Ubiproteomes in a single experiment. We
chose a single time point of EGF stimulation (10min), and
performed three biological replicates of both the ‘endogenous’
and the ‘TAP’ puriﬁcations. Remarkably, 73.2% (endogenous)
and 85.2% (TAP) of proteins were identiﬁed in at least two
experiments, indicating a high level of reproducibility. Experi-
ment size and features are reported in Supplementary Table S1
and in Supplementary Figure S2.
As an initial step in our analysis, we employed a multi-
layered strategy to deﬁne the size and speciﬁcity of the
identiﬁed Ubiproteomes (Figure 2A). To obtain ‘high-con-
ﬁdence data sets’ of quantiﬁed proteins, we adopted four
ﬁltering criteria described in detail in the Experimental
Procedures. By these criteria, from 11722 non-redundant
(NR) peptide sequences (corresponding to 1765 proteins)
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based proteome comprising 1175 unambiguously identiﬁed
and quantiﬁed proteins (Figure 2A and Supplementary Table
S1). In the case of the TAP approach, we unambiguously
identiﬁed 582 proteins (from 3173 NR peptides, corresponding
to 744 proteins; Figure 2A and Supplementary Table S1).
In both cases, the identiﬁcation of short-lived proteins
and monoubiquitinated proteins demonstrates that the two
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Figure 1 Preparation of samples for MS-based proteomics analysis. (A) B82L-EGFR cells stably transfected with FLAG-6His-Ub were ﬁxed at the indicated
time points after doxycycline induction (4mg/ml) and stained with anti-FLAG antibody (red). Nuclei were DAPI stained (blue). (B) Parallel samples, treated as in A, were
lysed and immunoblotted (IB) as indicated. (C) Lysates as in B, were IB with anti-Ub antibody to compare the levels of expression of endogenous and tagged Ub.
(D) B82L-EGFR cells stably transfected with FLAG-6His-Ub were induced with doxycycline for 48h and stimulated with EGF or left untreated. Lysates (2mg) were
immunoprecipitated (IP) and IB as indicated. (E, F) Quality control of a representative ‘TAP’ puriﬁcation (experiment FW1, see Experimental Procedures and Results).
B82L-EGFR cells induced for 48h with doxycycline were stimulated with EGF (100ng/ml) for 10min or left untreated. Total cell lysates were analyzed by IB with the
indicated antibodies before mixing them (1:1) for the puriﬁcation (E). Aliquots from each step of the puriﬁcation procedure were analyzed by IB with anti-FLAG antibody.
The amount of loaded samples is expressed as % of total sample volume (F). (G, H) Quality control of a representative ‘endogenous’ puriﬁcation (experiment FW2, see
ExperimentalProceduresandResults).LysatesfromEGF-treated(100ng/ml,10min)oruntreatedHeLacellswereanalyzedasinE(G).Thepuriﬁcationprocedurewas
controlled as in F, except that an anti-Ub antibody (P4D1) was used (H). Note that the EGF-induced increase in the total ubiquitinated protein content is not proportional
to the increase in protein tyrosine phosphorylation. This is expected as the vast majority of Ub-modiﬁed species in the cell is represented by constitutively ubiquitinated
proteins, destined to proteasomal degradation.
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Figure 2 The steady-state Ubiproteome. (A) Size and features of steady-state Ubiproteomes identiﬁed with the endogenous and TAP approaches. NR, number of
non-redundant proteins from the two approaches. Overlap End/TAP, number of proteins identiﬁed in common between the two approaches. P, signiﬁcance P-value of
the overlap (Fisher’s exact test). (B) Validation of candidates (see also additional examples in Supplementary Figure S3). Cells (293T) were transfected with the
indicatedconstructsandlysedafter24h.LysateswereIPanti-FLAG(candidates)andIBwithanti-HA(Ub)antibodytoevaluatetheubiquitinationlevelofthecandidates.
(C, D) MS/MS spectra of the identiﬁed ubiquitination site of ubiquitin-conjugating enzyme Ube2N (Ubc13). (C) Fragmentation pattern of the quadruple-charged tryptic
peptideofUbe2NderivedfromHeLacellularextracts.(D)FragmentationpatternofthetriplychargedtrypticpeptideofUbe2NderivedfromB82L-EGFRcellularextracts.
The y-series of ions (C terminus containing fragments) are labeled in blue and b-series (N terminus containing fragments) are labeled in red.
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proteins together with histones argues for the efﬁciency of the
solubilization procedure. This said, we acknowledge that the
identiﬁed Ubiproteomes are unlikely to represent the full
repertoire of ubiquitinated proteins found in mammalian cell,
although they are the most complete set of ubiquitinated
proteins identiﬁed so far (Supplementary Figure S3).
To validate our Ubiproteomes, we tested several candidates by
direct immunoprecipitation (IP; Figure 2B and Supplementary
Figure S3). On the basis of these results, we estimated a false-
positive rate of B5% for the ‘endogenous’ approach (2 out of 38
tested candidates were not validated by IP) and B3% for the TAP
approach (1 out of 30 candidates was not validated, see legend to
Supplementary Figure S3 for details). The non-validated proteins
possibly represent the fraction of Ub-interacting proteins co-
puriﬁed during the procedure, as they were absent in the control
puriﬁcations (Supplementary Table S1).
We also analyzed the overlap between the endogenous and
the TAP Ubiproteomes. One limitation of our study is that
the two approaches were optimized in two different cell
types. Nevertheless, 284 proteins were identiﬁed in common
between the two approaches (P¼2.22 10
 176, Figure 2A and
Supplementary Table S1). This high degree of overlap is
remarkable given that the two cellular settings are very
different (a human cervical cancer cell line versus a mouse
ﬁbroblast cell line).
Of note, we identiﬁed 31 ubiquitination sites in 21 target
proteins, some of which were previously unknown. The
complete list of identiﬁed sites is shown in Supplementary
Table S1. A representative instance of these ﬁndings is the
E2-conjugating enzyme Ubc13, for which the same modiﬁed
K was found in both the human and the mouse cell line
(Figure 2C and D, see also legend to Supplementary Table S1
for details).
The EGF-Ubiproteome
We next exploited the quantitative information embedded in
the SILAC data to identify the EGF-regulated Ubiproteome.
Protein quantitation was performed automatically using
MaxQuant, as described previously (Cox and Mann, 2008).
Ratios for proteins were determined as the median of all
measured peptide ratios for a given protein, to minimize the
effect of outliers (Supplementary Figure S4). To identify
proteins that were most signiﬁcantly regulated by EGF, we
employed a stringent three-tiered selection process. Starting
from the two steady-state Ubiproteomes, we discarded
proteins with a P-value 40.1 (Signiﬁcance B, see Cox and
Mann, 2008) and a coefﬁcient of variability 410 (ﬁlter A in
Figure3A, see Supplementary information fordetails).Finally,
we applied a manual curation step selecting only those
proteins displaying the same trend of regulation in the
experimental replicates (ﬁlter B, Figure 3A). Additionally, we
veriﬁed that protein levels did not change upon EGF
stimulation in the whole proteomes (Supplementary Figure
S5). By these stringent criteria, we concluded that B15% of
the steady-state Ubiproteome was EGF regulated at 10min
after stimulation; 176 of 1175 proteins in the endogenous
approach and 105 of 582 proteins in the TAP approach
(Figure 3A and Supplementary Table S2). Interestingly,
both hyper- and hypoubiquitinated proteins were detected
(134 hyper- and 42 hypoubiquitinated in the endogenous
approach, 58 hyper- and 47 hypoubiquitinated in the TAP
approach; Figure 3B and C and Supplementary Table S2),
indicating that EGFR-mediated signaling can modulate the Ub
network in both directions. This ﬁnding is supported by the
presence of both ubiquitinating and deubiquitinating enzymes
in the EGF-Ubiproteome (see below).
The major limitation of our study is that our EGF-
Ubiproteomes were not time resolved. Indeed, while we
identiﬁed virtually all proteins known to be ubiquitinated
upon EGF stimulation in both Ubiproteomes, only 16 out of
92 proteins were commonly classiﬁed as regulated at 10min of
EGF stimulation (when the proteomic analysis was per-
formed). Of these, 14 proteins (10 hyperubiquitinated and 4
hypoubiquitinated) were regulated in the same direction in
both approaches (Supplementary Table S1). Twenty-seven
additional proteins were found to be regulated only in the
endogenous approach (24 hyperubiquitinated and 3 hypoubi-
quitinated), while 49 additional proteins were identiﬁed only
in the TAP approach (23 hyperubiquitinated and 26 hypoubi-
quitinated; see Supplementary Table S1). While cellular
speciﬁcity may account for some of these variations
(Figure 3A), different kinetics of ubiquitination in the two
cellular systems might also affect the extent of the overlap. As
a case in point, the endocytic adaptor protein Eps15 is
ubiquitinated following EGF stimulation (Polo et al, 2002).
Eps15waspresentintheB82L-EGFR (TAP)butnotintheHeLa
(endogenous) EGF-Ubiproteome (Supplementary Table S2).
Immunoblot analysis revealed that the kinetics of Eps15
ubiquitination upon EGF stimulation differed in the two
cellular systems: at 10min Eps15 was ubiquitinated in B82L-
EGFR, but not in HeLa, cells (Figure 3D). Similar results were
obtained for Rabex-5 and Hgs (data not shown).
The concept that the two EGF-Ubiproteomes might repre-
sent different time-resolved snapshots of the same network in
two cellular systems is further supported by results derived
from protein ontology analysis. We classiﬁed the EGF-
regulated Ubiproteomes by PANTHER (Protein ANalysis
THrough Evolutionary Relationships; Wiesner et al, 2007),
and analyzed the enrichment of ontology terms. We identiﬁed
29 biological process (BP) terms as enriched (P-value o0.05)
in the endogenous data set and 17 BP terms in the TAP data set
(Figure 3E and F). Nine identical and three closely related BP
terms were found in both EGF-Ubiproteomes: 41 and 70% of
BP terms in the endogenous and TAP Ubiproteomes, respec-
tively (reported in bold in Figure 3E and F). Therefore,
regardless of the different experimental strategies employed
and, more importantly, of the different experimental models,
the two EGF-regulated Ubiproteomes show a high level of
conservation in the cellular mechanisms that they represent.
Chain topology of the EGF-regulated Ubiproteome
To evaluate possible changes in the relative abundance of the
different chains upon EGF stimulation, we quantiﬁed the Ub
‘signature’ peptides by SILAC (see Meierhofer et al, 2008 and
Supplementary Table S3). With the TAPapproach,MSanalysis
revealed an increase in the K63-, K11- and K6-chain modiﬁca-
tions after EGF stimulation (Supplementary Table S3 and
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approach only K63 linkages accumulated, although to a lesser
degree (Supplementary Table S3, see its legend for details).
A possible explanation for this discrepancy is that the tagged
Ub could affect the activity of speciﬁc E3s or DUBs, due to the
extra N terminus present in the molecule. This would
cause indirect changes in the level of speciﬁc chain linkages.
To evaluate this possibility, we quantiﬁed the Ub ‘signature’
peptides before and after FLAG-His-Ub induction. No
signiﬁcant changes were evident when comparing the two
conditions, indicating that, at least in our controlled settings,
the expression of tagged Ub per se does not change the level of
speciﬁc Ub chains (Supplementary Figure S7).
These initial, yet not conclusive, results prompted us to
validate the MS analysis using the recently developed K48 and
K63 linkage-speciﬁc antibodies (Newton et al, 2008). A strong
colocalization of EGFR-containing vesicles and the anti-K63
antibody was observed upon EGF stimulation, whereas no
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ontherightyaxis(redhistograms).Theexpectedenrichment(grayhistograms)isobtainedfromtheratiobetweenthetotalnumberofgenesinthetermandthetotalnumberof
genesinthegenome.Thestatisticalsigniﬁcancebetweenobservedandexpectedenrichments(scatteredline)wasdeterminedbyFisher’sexacttestandisplottedonthelefty
axis as  log10 of P-values; the higher the value, the more signiﬁcant the enrichment ( log10 of P¼0.05 is 1.30). In bold, the 12 pathways found in both EGF-Ubiproteomes
(three are closely related: protein/amino-acid biosynthesis; intracellular/other intracellular protein trafﬁc; fatty acid biosynthesis/fatty acid and steroid metabolism).
Figure 4 EGF induces K63-speciﬁc ubiquitination. (A)HeLa cells grown on coverslips were serum-starved for 4h and treated for 10min at 371C with rhodamine-EGF
(0.5mg/ml, red) or left untreated (left panels). Ub (green) was detected with the FK2 antibody that recognizes both mono- and poly-Ub (upper panel) or antibodies that
speciﬁcally recognize K63- or K48-linked Ub chains (middle and lower panels, respectively). Confocal images are shown. Blue, DAPI staining. Bar, 18mm. (B) Lysates
(1mg) from HeLa cells stimulated with EGF (100ng/ml) for the indicated times were subjected to IP with K63-Ub or K48-Ub-chain-speciﬁc antibodies or the FK2
antibody.IPsandlysates(50mg/lane)wereIBwiththe indicatedantibodies. P4D1antibodywasusedfortheanti-UbIB.Asterisk,unspeciﬁcband. Notethatbothspliced
forms of Nedd4L appear to be ubiquitinated.
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(Figure 4A). The FK2 antibody, which recognizes all types of
poly-Ub chains equally well (Supplementary Figure S8),
displayed an intermediate phenotype (Figure 4A).
We then assessed some validated hits from our EGF-
Ubiproteome by IP with linkage-speciﬁc antibodies and
immunoblot analysis. Upon EGF stimulation, EGFR is almost
exclusively modiﬁed by K63-linked chains (Figure 4B), in
agreement with previous ﬁndings (Huang et al, 2006). Cbl,
which is degraded upon EGF stimulation (Magniﬁco et al,
2003), is also strongly modiﬁed by K63 chains (Figure 4B).
Notably, we also validated two novel EGF-induced ubiquiti-
nated targets, namely, Nedd4L and SLC3A2, and showed that
they carry almost exclusively K63-linked chains (Figure 4B).
These results strengthen the idea that K63 might not only be
the preferred signal for receptor internalization as previously
suggested (Lauwers et al, 2010), but also be the major Ub-
based signal transmitted by the active EGFR.
Network analysis of the EGF-regulated
Ubiproteome
To obtain a higher-resolution molecular picture of the EGF-
regulated Ub network, we analyzed the NR-EGF-Ubiproteome
(265 proteins, Supplementary Table S2) through the Ingenuity
Pathways Knowledge Software (Ingenuity
s Systems,
http://www.ingenuity.com) and looked for enrichment of
canonical pathways. We identiﬁed 85 proteins that were
signiﬁcantly enriched in 39 pathways(P-value o0.05, Fisher’s
exact test), of which 13 pathways (67 proteins) remained
signiﬁcant after multiple test correction (P-value o0.05,
Benjamini and Hochberg False Discovery Rate; Figure 5A). In
additiontowell-establishedliaisons(suchasthosewithclathrin
and caveolar endocytosis, or virus entry pathways), the EGF-
Ubiproteome intersects many circuitries of intracellular signal-
ing,suggestingcrosstalkbetweenEGFR-activatedpathwaysand
other signaling pathways through the Ub network.
We further organized the EGF-Ubiproteome into distinct
interaction networks through the Ingenuity Pathways Knowl-
edge Software to predict how the Ub modiﬁcation might
inﬂuence the molecular crosstalk between proteins that
interact biochemically and/or genetically. The proteins of the
EGF-Ubiproteome are grouped into 30 networks, of which 11
reached statistical signiﬁcance (Po0.0001, random permuta-
tion test, Figure 5B). Interestingly, unsupervised clustering of
these 11 networks, based on the number of common proteins,
revealed two main clusters (C1 and C2, Figure 5B). Functional
annotation of molecules in these networks through the
Molecular Signature Database (MSigDB) (Subramanian et al,
2007) revealed that cluster C1 is enriched in proliferation
and inﬂammation signatures, whereas cluster C2 contains
networks enriched in apoptosis, adhesion and cell cycle
signatures. Interestingly, network 1 does not belong to any
cluster(i.e.,noproteinsaresharedwithothernetworks)andis
speciﬁcally enriched in ribosomal proteins (see Figure 5B and
Supplementary information for details).
TheabilityofEGF-Ubiproteomeproteinstonucleateclusters
of interactions involved in diverse functions suggests that
these proteins might act as organizational ‘hubs’, proteins that
can establish multiple protein/protein interactions and there-
by regulate the organization of networks. This is indeed
the case, as proteins of the EGF-Ubiproteome displayed
signiﬁcantly higher connectivity than randomly generated
lists of proteins (5000 lists were tested; Figure 5C and
SupplementaryTableS3).Intotal,65hubs(deﬁnedasproteins
with X5 interactors) were identiﬁed in the EGF-Ubiproteome
(Supplementary Table S3). Among them, Hgs and Cbl,
which have already been demonstrated to be critical for
many intracellular signaling networks (Schmidt and Dikic,
2005; Zwang and Yarden, 2009), displayed the highest
connectivity.
Intersection of the EGF-induced Ubi- and
phosphotyrosine proteomes
EGF binding to its receptor triggers a series of phosphorylation
events that culminates in transcriptional activation and the
mitogenic response. Proteins that undergo EGF-triggered
phosphorylation have recently been described in three EGF-
inducedphosphotyrosine(pY)proteomes (Blagoev etal,2004;
Oyamaet al, 2009; Hammond et al, 2010). Acomparison of our
EGF-Ubiproteome with these EGF-pY proteomes, as well as
with the phospho.ELM database (Diella et al, 2008) that
contains experimentally validated pY-containing proteins,
revealed a signiﬁcant overlap between ubiquitinated and pY
proteins (Figure 6A, Supplementary Table S3). In total, 23%
(61 of 265) of the EGF-Ubiproteome proteins are also tyrosine
phosphorylated (Figure 6A, Supplementary Table S3).
Pathway analysis of these 61 Ub/pY-containing proteins
revealed a signiﬁcant enrichment in endocytic and signal-
transduction pathways (Figure 6B). Finally, ‘hub analysis’
revealed that Ub/pY-containing proteins areenriched in highly
connected proteins to an even greater extent than Ub-contain-
ing proteins alone (Figure 6C). These data point to a complex
Figure 5 Pathway analysis of the EGF-Ubiproteome. (A) Ingenuity pathway analysis. Enrichment plots of canonical pathways (x axis) built on the list of 265 EGF-
regulated proteins Ubiproteome (sum of the endogenous and the TAP approaches). The percentage enrichment, based on the ratio between the number of SILAC
regulated proteins and the total number of proteins annotated in each pathway, is plotted on the right y axis (black line). The signiﬁcance of the enrichment (gray bars)
was calculated using the Benjiamini Hochberg multiple testing correction and is plotted on the left y axis as  log10 of P-values; the higher the value, the more signiﬁcant
the enrichment ( log10 of P¼0.05 is 1.30). (B) Network analysis of the EGF-Ubiproteome. Left panel, list of the 11 networks that reach high statistical signiﬁcance
(Po0.0001, see Supplementary information). Network, network ID number. Molecules, number of EGF-Ubiproteome proteins/total number of network proteins.
Description, functional category based on MSigDB analysis. Relevance, percentage of proteins in functional categories relative to total proteins in the network. Right
panel,unsupervisedhierarchicalclusteringoftheidentiﬁednetworks.Clustersweregeneratedbasedonthenumberofproteinsincommonbetweennetworksdividedby
the total number of proteins present in each network (Supplementary Table S3). The percentage of shared proteins is indicated by color code (white, 0%; red, X50%).
(C) Hub analysis. The number of random sets of proteins containing hubs (proteins with more X5, 10 interactors as annotated in the BioGRID human interaction
database(Starket al,2006)) isdisplayed. Thered dashed lineindicates the position inthe distributionof the EGF-Ubiproteome (265 proteins). yaxis, number ofrandom
sets containing hubs (deﬁned as above), x axis number of proteins deﬁned as hubs. P-values indicate signiﬁcance of the enrichment of hubs in the EGF-Ubiproteome
based on this ‘null’ distribution.
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the ﬂow of information from the receptor to downstream
signaling molecules is driven by two complementary and
interlinked enzymatic cascades: kinases/phosphatases and
E3 ligases/DUBs.
Crosstalk between the EGFR and EphA2
signaling receptors
To provide a proof of principle of the biological relevance of
our ﬁndings, we focused on EphA2, a receptor tyrosine kinase
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(Pasquale, 2008). We started from the observation that
proteins of the EGF-Ubiproteome are indeed enriched in the
Ephrin receptor signaling pathway(s) (Figure 5A) and that
EphA2 displayed a ratio of 2.67 (Supplementary Table S2).
As an initial step, we validated the MS data. Upon EGF
stimulation, we observed an increase in both the tyrosine
phosphorylation and ubiquitination of EphA2, indicating a
crosstalk between the two receptors (Figure 7A and Supple-
mentary Figure S9A). Interestingly, the crosstalk was unidir-
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to EGFR activation (Figure 7A).
We then assessed how the signal is transmitted from EGFR
to EphA2. The tworeceptors do not appear to stably physically
interact, as determined by co-IP (data not shown). However,
the kinase activity, but not the cytoplasmic tail of the EGFR, is
required for both modiﬁcations of EphA2 (Supplementary
Figure S9A). One possibility is that EphA2 phosphorylation
might be a prerequisite for Cbl recruitment, as this E3 ligase
has previously been shown to be involved in ligand-mediated
EphA2 degradation (Walker-Daniels et al, 2002; Wang et al,
2002). While this hypothesis deserves further investigation,
we observed that prolonged EGF stimulation did not result in
EphA2 degradation, indicating that EGF-induced EphA2
ubiquitinationdoesnotsignalfordegradation(Supplementary
Figure S9C and data not shown).
What is then the functional consequence of EphA2
ubiquitination? One obvious possibility is internalization.
Thus, we investigated the effect of EGF stimulation on
the localization of EphA2 by confocal microscopy. No strong
changes were visible on the total level or distribution
of EphA2, although a partial co-internalization with EGFR
upon EGF activation was clearly detectable (Supplementary
Figure S9B).
While these data clearly demonstrate that EphA2 is a novel,
downstream ubiquitinated target of EGFR, the role exerted
by EphA2 ubiquitination on EGF signaling remains to be
established. To start to assess the relevance of EphA2 to EGFR
biology, we turned to the normal human breast epithelial cell
line MCF10A that expresses both EphA2 and EGFR at
signiﬁcant levels (Supplementary Figure S9C). siRNA knock-
down (KD) of EphA2 resulted in reduced EGF-induced
proliferation (Figure 7B) and migration (Figure 7C), indicating
that this receptor is critically involved in these EGFR biological
readout. These results, although preliminary, set the stage for
future ‘in depth’ molecularstudies and highlight the ‘resource’
feature of our EGF-Ubiproteome.
Discussion
Although the Ub system has been intensively investigated in
the past two decades, its impact on cellular homeostasis
remains largely unexplored. This is particularly true for the
signalingfunctionsofubiquitination,whichhaveemergedasa
major regulatory mechanism of signal transduction (Chen
and Sun, 2009). Here, we report the ﬁrst analysis of the
EGF-Ubiproteome, which reveals an unexpected degree of
pervasiveness of growth factor-induced ubiquitination across
severalsignalingpathways,andasimilarlyunanticipatedlevel
of integration between two distinct types of PTM-based
signaling.
The steady-state Ubiproteome
Weinitiallydeﬁnedthesteady-stateUbiproteomesinHeLaand
B82-EGFR cells. By combining the two, we deﬁned a list
of 1472 NR proteins, which constitutes the largestcollection of
ubiquitinated proteins reported so far in mammals (Figure 2A
and Supplementary Figure S3). The comparison with pre-
viously published Ubiproteomes shows a signiﬁcant overlap,
ranging from B60% for data sets obtained in non-stringent
conditions to B75% for those obtained under stringent
denaturing conditions (Supplementary Figure S3). A distinct
feature of our Ubiproteome is that it has been extensively
validated. The effectiveness of our strategy is underscored
by the fact that 495% of the tested candidates were shown to
be bona ﬁde ubiquitinated proteins(seeSupplementary Figure
S3 and its legend). In addition, there is a substantial overlap
between the HeLa (endogenous) and B83L-EGFR (TAP)
Ubiproteomes, with B50% of ‘mouse proteins’ being present
in the list of ‘human proteins’.
The EGF-Ubiproteome
Weused a stringentstatistical analysisto identify 265 proteins,
whose ubiquitination was regulated by activated EGFR. Thus,
B18% of the steady-state Ubiproteome (265 of 1472) is
modulated byan exogenous signal. As a kinetic analysis of the
EGF-Ubiproteome was not performed, the above percentage
likely underestimates the impact of EGFR on the Ub network.
A ﬁrst obvious question is how EGFR, a receptor tyrosine
kinase, transmits signals to the ubiquitination machinery to
execute the modiﬁcation of such a vast number of proteins.
There is scarce literature on this topic. One known circuitry
involvesthe E3ligase Cbl,which binds topY-sites on theEGFR
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activated (Kassenbrock and Anderson, 2004). This leads to
EGFR ubiquitination and might also facilitate ubiquitination
of other receptor-associated molecules, among which Cbl
itself (Magniﬁco et al, 2003). Of note, the presence of non-
proteolytic Ub chains on this E3 ligase (Figure4B) suggests the
existence of additional modes of regulation for this key Ub
network player. Other effector enzymes (E2s, E3s, DUBs)
might also be regulated though EGFR-mediated tyrosine
phosphorylation. However, only three E3s (Cbl, Cbl-b and
Huwe-1) and no E2s or DUBs have been identiﬁed in EGFR
pY proteomes (Blagoev et al, 2004; Oyama et al, 2009).
Conversely, we identiﬁed scores of Ub machinery enzymes in
theEGF-Ubiproteome.TheseincludeE3s(Cbl,Cbl-b,Nedd4-2,
RNF149, Rnf25, Huwe1, ZNF207, Znf319, Hectd1and HERC4),
E2s (Ube2O, UBE2Z, UBA2) and DUBs (JOSD1, USP15,
ATXN3, USP11, USP5, USP34). The involvement of such a
large number of effectors was unexpected. It appears,
therefore, that regardless of the initial triggering mechanism
(which must necessarily involve the kinase activity of the
EGFR), the Ub signal is rapidly transmitted to, and ampliﬁed
through, the Ub machinery. Similar to the phosphorylation
cascade, in which critical enzymes such as kinases and
phosphatases are often activated by phosphorylation, Ub
enzymes may be regulated by ubiquitination (see for example
Woelk et al, 2006; Ring1B (Ben-Saadon et al, 2006)). The
impact of EGFR-mediated ubiquitination on the activityof E3s,
E2s and DUBs warrants further investigation.
A second line of EGF-regulated ubiquitination events
impinges on endocytic and signaling proteins. While these
pathways are known factors in the Ub network, the magnitude
of their involvement is somewhat surprising. EGF-regulated
ubiquitination is involved in both clathrin-dependent and
-independent endocytosis, in dozens of intracellular signaling
circuitries, in cell-to-cell and cell-to-substrate adhesion
mechanisms, and in actin remodeling. It seems, therefore,
that EGFR-dependent ubiquitination intersects all aspects of
signaling; the biochemical circuitries (such as PI3K-, 14-3-3-,
JAK/STAT- and PTEN-related); the components that confer
spatial and temporal dimensions to signaling (endocytosis);
the coordinated modiﬁcations in cyto-architecture and rela-
tionships with the external milieu (actin, integrins, ephrins)
that are necessary for the execution of complex signaling
programs. As a proof of principle we investigated the
functional link between EGFR and EphA2 and we demon-
strated that activation of this signaling receptor is indeed
required for EGF-mediated proliferation and migration
(Figure 7). This result is particularly relevant considering that
downregulation of EphA2 has been shown to decrease
malignant phenotypes of cancer cells in vitro and to inhibit
tumorgrowthin severalmouse cancer models (Pasquale, 2008
and references therein). How this and other crosstalk are
achieved, in mechanistic terms, remains to be elucidated. The
emerging picture, however, is that the impact of ubiquitination
on receptor-activated pathways might be as profound and as
vast as the canonical pY-based network.
Finally, a third line of ubiquitinated proteins connects EGFR
activity to manyotheraspects of cellular physiology, including
DNA repair, nuclear transport, mRNA processing, various
metabolic pathways and ribosome biogenesis. In the latter
case, recent literature suggests that ubiquitination and
degradation of ribosomal proteins might be a general
mechanism adopted by mammalian cells to control ribosome
production that can be adjusted according to cellular needs
(Caldarola et al, 2009 and references therein). It remains to
be established whether the EGFR-dependent ubiquitination of
ribosomal proteins, uncovered herein, serves to regulate their
degradation or has other, yet to be discovered, non-proteolytic
functions.
One intriguing connection concerns EGF regulation of the
solute carriers (SLCs)/transporters (validation of SLC3A2
is reported in Figure 4). These molecules are gatekeepers for
cells and organelles, and control the uptake and efﬂux of
important metabolites such as sugars, amino acids, nucleo-
tides and inorganic ions. Almost all categories of SLCs are
represented in our EGF-induced Ubiproteome, and all are
hyperubiquitinated upon EGF stimulation (Supplementary
Table S2). A growing body of biochemical and biophysical
evidence suggests that these transporters are modulated by
trafﬁcking, and that the Ub modiﬁcation is the signal for their
internalization and/or lysosomal degradation (Miranda and
Sorkin, 2007). Moreover, while transactivation of EGFR
elicited by activation of the Na(þ)/K(þ)-ATPase has been
described (Xie, 2003), our data demonstrate, for the ﬁrst time,
the EGF-induced regulation of SLC proteins. In this context, it
is worth mentioning that EGFR is able to interact directly with
SLC5A1/SGLT1, stabilizing the sodium/glucose cotransporter
and facilitating glucose transport into cells (Weihua et al,
2008). The mechanisms through which EGFR can trigger the
ubiquitination of SLCs, and the ultimate functional signiﬁ-
cance of the modiﬁcation remain to be elucidated: a line of
investigation that may have important implications also for
neurological diseases (Tzingounis and Wadiche, 2007) and
cancer (Engelman and Cantley, 2008; Nicklin et al, 2009),
wherealterationsofSLCshaveanimportantpathogeneticrole.
Connectivity of the EGF-Ubiproteome
The EGF-Ubiproteome displayed remarkable connectivity—a
possible indication of a wide pervasiveness of this network in
cell regulation—organized into three levels. The ﬁrst level is
represented by intra-network connectivity. Indeed, the pro-
teinsoftheEGF-Ubiproteome groupedintotwomajorclusters,
enriched in proliferation/inﬂammation and apoptosis/adhe-
sion/cell cycle signatures (Figure 5). This result suggests that
the EGF-regulated Ub network is a rather compact infrastruc-
ture, which allows coordinated control by EGFR of a multi-
plicity of signaling mechanisms. This ‘core’ regulatory
network then reaches out to intersect (level 2 of connectivity)
virtuallyeveryaspect of intracellular signaling, as discussed in
the previous section.
Finally, a third level of connectivity is represented by the
considerable overlap between the EGF-induced Ubiproteome
and pY proteome. These two PTM-based networks can be
conceptualized as two overlapping, diffusely interconnected,
matrices through which the EGFR transduces signals to
make them readable to the cell. How this is achieved remains
to be established and will require high-resolution studies,
probably on a protein-by-protein basis. In principle, ubiquiti-
nation might control the stability and/or degradation of
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EGFR might exert dual control on the activation (through pY)
anddeactivation(throughUb)ofsignalingpathways.Wenote,
however, that the EGFR mostly induces K63-linked ubiquitina-
tion (Figure 4). This modiﬁcation has been linked to the
signalingabilityofUb,ratherthantoitsdegradationproperties
(Woelk et al, 2007). It is thus possible that EGFR-induced
ubiquitination adds a layer of signaling complexity to the
canonical pY-based circuitry of EGFR signaling.
The ability of the proteins of the EGF-Ubiproteome to
nucleate clusters of interactions was mirrored by their
enrichment in ‘hubs’, which became even more evident
when dually modiﬁed (pYand Ub) proteins were considered.
Hubs are proteins that form critical interconnections between
signaling pathways and are points of fragility of signaling
networks (Amit et al, 2007). As such, they represent ideal
targets for pharmacological intervention. However, detailed
molecular knowledge of the mechanisms of interconnectivity
of hubs is indispensable to predict the results of ‘hub
interference’. Our results might thus be relevant for the
identiﬁcation of therapeutic targets, and to determine appro-
priate strategies of intervention in pathological conditions in
which subversion of signaling by EGFR (and other receptor
tyrosine kinases) is relevant, such as cancer.
Materials and methods
Reagents, constructs and cell culture
EGF was purchased from Intergen (Oxford, UK), rhodamine-EGF was
from Molecular Probes. Puromycin, doxycyline, FLAG peptide, trypsin
(proteomic grade), DTT, iodacetamide, chloroacetamide and
N-ethylmaleimide, ephrinA1/A5 extracellular domain/Fc chimera,
L-Arg
12C6,
14N4-HCl, L-Arg
13C6,
15N4-HCl, L-Lys
12C6,
14N2-HCl and
L-Lys
13C6,
15N2-HCl were from Sigma. Imidazole and urea were from
Carlo Erba. EDTA-free protease inhibitor cocktail tablets were from
Roche. Ni-NTA agarose beads were from Qiagen. (K speciﬁc only)Ubn
chains were from ENZO Life Sciences. Antibodies used were as
follows: monoclonal anti-FLAG (M2, Sigma), M2-agarose afﬁnity gel
(Sigma), monoclonal anti-HA (clone 16B12, Babco), anti-vinculin
(Sigma), monoclonal anti-Ub (P4D1, Santa Cruz and FK2, ENZO Life
Sciences), anti-K63 and K48 Ub-chain-speciﬁc antibodies (Genen-
tech), polyclonal anti-EGFR (directed against aa 1172–1186 of human
EGFR, produced in-house), anti-eps15 (monoclonal, produced
in-house), monoclonal anti-EphA2 (clone D7, Upstate) polyclonal
anti-EphA2 (clone C-20, Santa Cruz), polyclonal anti-SLC3A2 (H-300,
Santa Cruz), monoclonal anti-Cbl (BD), anti-phospho-ERK (Cell
Signaling), anti-phospho-AKT (Cell Signaling) and anti-pY (Clone
4G10, Upstate Biotechnology).
The engineering of FLAG-6His-Ub and GST-S5a is reported in
Supplementary information.
GST–S5a fusion protein and FK2 antibody were crosslinked using
AminoLink
s and CarboLinkt Coupling Gel (Pierce Biotechnology),
respectively, according to the manufacturer’s instructions. Avidin-
agarose beads used in the control puriﬁcation were from Pierce
Biotechnology.
B82L ﬁbroblasts expressing the human wild-type EGFR (B82L-wt),
kinase-defective EGFR (B82L-Kin
 ) and the COOH terminally trun-
cated EGFR at Tyr-958 (B82L-958) have been described previously
(Welsh et al, 1994). B82L-EGFR cells stably expressing FLAG-6His-Ub
were obtained by transfecting pSG213-FLAG-6His-Ub using LipofectA-
MINEt (Invitrogen). Cells were selected in medium containing
5mg/ml puromycine. Expression of FLAG-6His-Ub was induced by
adding doxycycline to the culture medium at a ﬁnal concentration of
4mg/ml. MCF10A cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium and F12 medium (DMEM-F12) supplemented with 5% horse
serum, hydrocortisone (0.5mg/ml), insulin (10mg/ml), cholera toxin
(50ng/ml), EGF (20ng/ml) and penicillin-streptomycin (100mg/ml
each). When serum-starved, cells were cultured in the same medium
devoid of serum and EGF.
Cell lysis and IP were performed as previously described (Penengo
et al, 2006). For the IPs with the anti-Ub antibodies, 500mg of HeLa
lysate was subjected to IP either with 20mg of FK2 antibody or 5mgo f
K63 Ub-chain-speciﬁc antibody for 2h at 41C, followed by 1h
incubation with Protein G-conjugated sepharose beads (Zymed).
Soluble EphrinA1 and A5 fusion proteins (EphrinA1-, EphrinA5–Fc)
wereobtainedbymixingEphrinA1/5withtheFcportionofhumanIgG
in a molar ratio 1:10. Preclustering was performed on ice for 1h.
Immunoﬂuorescence procedures, ablation of EphA2, BrdU incorpora-
tion and migration assays are in the Supplementary information.
The procedures for SILAC labeling and for the TAPand endogenous
(FK2) puriﬁcations are described in the Supplementary information.
LC-MS/MS analysis
Peptides were separated on a 15cm C18-reversed phase column
(75mm inner diameter) packed in-house with Reprosil (ReproSil-Pur
C18-AQ 3-mm resin, Dr Maisch), using a nanoﬂow HPLC system
(Agilent Technologies, Waldbronn, Germany or Proxeon, Proxeon
Biosystems, Odense, Denmark). The HPLC was coupled online via a
nanoelectrospray ion source (Proxeon Biosystems) to an LTQ-Orbitrap
mass spectrometer (Thermo Scientiﬁc). We used a 140min gradient
from 2 to 60% acetonitrile in 0.5% acetic acid at a ﬂow of 250nl/min.
The LTQ-Orbitrap was operated in the positive ion mode, with the
following acquisition cycle: a full scan (from m/z 300–2000) recorded
in the orbitrap analyzer at resolution R¼60000 followed by sequential
isolationandfragmentationoftheﬁvemost-intensepeptideionsinthe
LTQ analyzer by collisionally induced dissociation. The ‘lock mass’
option was enabled in all full scans to improve mass accuracy of
precursor ions (Olsen et al, 2005). Up to 500 sequenced ions were
dynamically excluded for 60s after sequencing. The maximum
allowed ﬁll time for an Orbitrap survey scan (ion target 1000000)
was 1s, and for an LTQ MS/MS scan (ion target 5000), 150ms.
Data analysis
The raw data ﬁles were analyzed with the in-house developed
quantitative proteomics software MaxQuant, version 1.0.11.5
(see Cox and Mann (2008) for details), which was used for peak list
generation, identiﬁcation and quantitation of SILAC pairs, and
ﬁltering. The software is supported by Mascot (version 2.2, Matrix
Science) as the database search engine for peptide identiﬁcation
(Perkinset al,1999). MS/MSspectrawere searched againstthe human
(endogenous Ub, HeLa cells) or mouse (FLAG-6His-Ub, B82L-EGFR
cells) International Protein Index(IPI) databases(versions 3.37). False
discovery rates (FDR) were controlled by searching in a concatenated
database consisting of the original protein sequences plus their
reversed versions, in which all Ks and Rs have been exchanged with
each other. Protein sequences of common contaminants, e.g., human
keratins and proteases used, were added to the database. Proteins and
peptides with an FDR41% were discarded. Posteriorerror probability
for peptides were calculated as described previously (Cox and Mann,
2008) and set to 1%. The initial mass tolerance in MS mode was set to
7p.p.m.andMS/MSmasstolerancewas0.5Da.FortheMascotsearch,
cysteine carbamidomethylation was searched as a ﬁxed modiﬁcation,
whereas N-acetyl (Protein), Oxidation (M) and GlyGly (K) were
searched as variable modiﬁcations. Labeled arginine (
13C6,
15N4) and
lysine (
13C6,
15N2) were speciﬁed as ﬁxed or variable modiﬁcations,
depending on prior knowledge of the parent ion for the Mascot
searches. Full tryptic speciﬁcity with up to two missed cleavages was
requiredand only peptidesof at least sixamino acids were considered.
By default, it was required that each protein group was identiﬁed by at
least one peptide unique to the assigned protein group.
Three independent biological replicates were measured for the
endogenous Ub and the overexpressed FLAG-6His-Ub experiments.
Two experiments were identical (forward: FW1, FW2) and one was
with swapped labels (reverse: REV). Raw ﬁles of technical and
biological replicates were analyzed together, whereas the ratios of the
REV experiments were inverted (1/ratio) in order to have a median
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of quantiﬁed proteins, we adopted four ﬁltering criteria, according to
which proteins should (i) be represented by at least two peptides, one
ofwhichshouldbeuniquefortheproteinsequence;(ii)beidentiﬁedin
at least two of the three biological replicates; (iii) be quantiﬁed on at
leastthreepeptidepairs(heavyandlightversionsofthesamepeptide),
referred to as ratio counts; (iv) not be present to a similar degree in the
control puriﬁcation (see Supplementary Table S1 and its legend for list
of contaminants present in the control puriﬁcation).
The ﬁltering procedure to deﬁne potential regulated proteins,
the identiﬁcation of ubiquitination sites and the quantitation of the
‘signature peptides’ are described in the Supplementary information.
Clustering and functional analysis
Bioinformatics analyses were performed with online tools or tools
available in-house, as described in the Supplementary information.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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